Literature DB >> 17299271

Endogenous expression of an anti-TAR aptamer reduces HIV-1 replication.

Gaëlle Kolb1, Sandrine Reigadas, Daniela Castanotto, Aurélie Faure, Michel Ventura, John J Rossi, Jean-Jacques Toulmé.   

Abstract

An anti-TAR RNA aptamer called R06, which binds tightly and specifically to the trans-activation responsive (TAR) element of the human immunodeficiency virus type 1 (HIV-1) through loop-loop interactions has been previously selected.(1) We used HIV-based retroviral vectors to express the R06 aptamer. Its synthesis was driven by the U16 snoRNA. We investigated the ability of this cassette to interfere with TAR-mediated transcription using HeLa P4 cells stably expressing the beta-galactosidase gene under the control of the HIV-1 5'LTR. We demonstrated that, upon HIV-1 infection, the beta-galactosidase activity was reduced in cells expressing the nucleolar U16-R06 transcript. The replication of HIV-1 in these cells was also reduced as shown by quantification of the HIV-1 protease gene 24 h post-infection. This effect was specific and related to the formation of R06 TAR complex as an aptamer with a mutated loop, which was no longer able to bind to TAR, did not show any effect. The nucleolus is likely a compartment of interest for targeting the TAR-protein complex responsible for the trans-activation of transcription of the HIV-1 genome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17299271     DOI: 10.4161/rna.3.4.3811

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  19 in total

1.  Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase.

Authors:  Jeffrey J DeStefano; Gauri R Nair
Journal:  Oligonucleotides       Date:  2008-06

Review 2.  Aptamer-based targeted therapy.

Authors:  Guizhi Zhu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-08-17       Impact factor: 15.470

3.  Inhibition of early stages of HIV-1 assembly by INI1/hSNF5 transdominant negative mutant S6.

Authors:  Jennifer Cano; Ganjam V Kalpana
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

4.  Robust suppression of HIV replication by intracellularly expressed reverse transcriptase aptamers is independent of ribozyme processing.

Authors:  Margaret J Lange; Tarun K Sharma; Angela S Whatley; Linda A Landon; Michael A Tempesta; Marc C Johnson; Donald H Burke
Journal:  Mol Ther       Date:  2012-09-04       Impact factor: 11.454

5.  Inhibition of HIV Replication by Cyclic and Hairpin PNAs Targeting the HIV-1 TAR RNA Loop.

Authors:  Gregory Upert; Audrey Di Giorgio; Alok Upadhyay; Dinesh Manvar; Nootan Pandey; Virendra N Pandey; Nadia Patino
Journal:  J Nucleic Acids       Date:  2012-09-17

6.  Prostate-specific RNA aptamer: promising nucleic acid antibody-like cancer detection.

Authors:  Karina Marangoni; Adriana F Neves; Rafael M Rocha; Paulo R Faria; Patrícia T Alves; Aline G Souza; Patrícia T Fujimura; Fabiana A A Santos; Thaise G Araújo; Laura S Ward; Luiz R Goulart
Journal:  Sci Rep       Date:  2015-07-15       Impact factor: 4.379

Review 7.  Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets.

Authors:  Didier Meseure; Kinan Drak Alsibai; Andre Nicolas; Ivan Bieche; Antonin Morillon
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

8.  Anti-HCV RNA Aptamers Targeting the Genomic cis-Acting Replication Element.

Authors:  Soledad Marton; Beatriz Berzal-Herranz; Eva Garmendia; Francisco J Cueto; Alfredo Berzal-Herranz
Journal:  Pharmaceuticals (Basel)       Date:  2011-12-28

9.  High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication.

Authors:  Sonald Duclair; Archana Gautam; Andrew Ellington; Vinayaka R Prasad
Journal:  Mol Ther Nucleic Acids       Date:  2015-02-17       Impact factor: 10.183

10.  Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy.

Authors:  Chi Han Li; Yangchao Chen
Journal:  Curr Genomics       Date:  2015-10       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.